drugset / Trial / NCT01241643

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

NCT01241643

Phase 2 Terminated 92 enrolled Cytheris SA
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II multicenter, open-labeled, controlled, randomized study assessing weekly doses of Interleukin-7 (CYT107)

Timeline

Start
2010-09
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Interleukin-7 Protein / enzyme biologic 20 ug/kg Subcutaneous